BridgeBio real-world study shows Attruby cuts ATTR-CM clinical worsening risk 34% vs Pfizer’s tafamidis

• BridgeBio reported peer-reviewed real-world study results in Cardiology and Therapy comparing its ATTR-CM drug Attruby to Pfizer’s tafamidis.
• Claims-data analysis found Attruby patients were less likely to show early clinical worsening than those starting tafamidis.
• Benefits appeared within weeks, supporting a potential argument for frontline use or switching from tafamidis in routine practice.
• Separate electronic health record-based comparative study is slated for release at a 2026 medical meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230747PRIMZONEFULLFEED9832475) on September 23, 2026, and is solely responsible for the information contained therein.